jCyte Inc. Announces First Patients Treated in JC02-88 Trial for Retinitis Pigmentosa

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--jCyte, Inc. is pleased to announce the first patients have been enrolled and treated in the JC02-88 study evaluating the safety and efficacy of jCell (famzeretcel) for the treatment of retinitis pigmentosa (RP). The jCell dose being studied in this trial is approximately 50% higher than the highest dose administered in previous jCyte clinical trials. Retinitis pigmentosa is a rare genetic disorder that leads to progressive loss of the rod and cone photore